Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pregyn is an antiseptic vaginal tablet containing dequalinium chloride, developed and marketed by MacroPhar for the treatment of bacterial vaginosis (BV). Dequalinium chloride is a quaternary ammonium cation that functions as a broad-spectrum antimicrobial agent. It is effective against a wide range of Gram-positive and Gram-negative bacteria, as well as certain fungi and protozoa. The drug exerts its therapeutic effect by increasing the permeability of bacterial cell membranes and inhibiting vital enzymatic activities, which leads to the loss of cellular components and subsequent cell death. As a non-antibiotic treatment, it serves as an alternative to traditional therapies like metronidazole or clindamycin, particularly in regions where it is approved as an over-the-counter or prescription generic product.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dequalinium chloride.